一种间充质干细胞在治疗薄型子宫内膜及宫腔黏连药物中的应用
By using specific PDGF-BB monoclonal antibodies in combination or alone with umbilical cord mesenchymal stem cells, the problem of insufficient efficacy in existing treatments for thin endometrium and intrauterine adhesions has been solved, resulting in reduced endometrial gland growth and fibrosis, and significantly improved pregnancy rates.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- REIN CELL ENG TECH (GUANGZHOU) CO LTD
- Filing Date
- 2026-01-27
- Publication Date
- 2026-07-17
AI Technical Summary
Existing drugs and stem cell therapies for treating thin endometrium and intrauterine adhesions have limited efficacy, particularly in improving pregnancy rates and endometrial thickness, and there is a lack of drugs that inhibit PDGF.
A drug composition is prepared by using a monoclonal antibody specifically targeting PDGF-BB and umbilical cord mesenchymal stem cells as active pharmaceutical ingredients, either in combination or alone, and combined with common drug excipients, for the treatment of thin endometrium and intrauterine adhesions.
It significantly promotes the growth of endometrial glands, reduces the degree of fibrosis, and improves the pregnancy rate. The combined use of monoclonal antibodies and stem cells is significantly more effective than using them alone, and significantly improves endometrial health.
Smart Images
Figure CN121574247B_ABST